UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2014 (June 13, 2014)

REGENERON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

New York

(State or other jurisdiction of incorporation)

Registrant’s telephone number, including area code: (914) 847-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

As described in Item 5.07 below, at the 2014 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 13, 2014 (the “Annual Meeting”), the Company’s shareholders approved the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “Plan”). The Plan was previously adopted by Regeneron’s Board of Directors (the “Board”) on April 4, 2014 based upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”).

A description of the material terms of the Plan is set forth on pages 82 – 87 of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2014 (the “Proxy Statement”) and is incorporated herein by reference. The description of the Plan is qualified in its entirety by reference to the full text of the Plan, which was filed as Appendix B to the Proxy Statement and is incorporated herein by reference.

In connection with the shareholder approval of the Plan, the Compensation Committee approved on June 13, 2014 forms of award agreements under the Plan, pursuant to which non-qualified stock options, incentive stock options and shares of restricted stock may be issued to the Company’s executive officers, and non-qualified stock options may be issued to the non-employee members of the Board. Copies of the forms of award agreements are filed as Exhibits 10.1, 10.2, 10.3 and 10.4 to this Current Report on Form 8-K, and are incorporated herein by reference.

At the Annual Meeting, the Company’s shareholders voted on the matters set forth below.

Proposal 1 – Election of Directors

The following nominees for Class II directors were elected to serve until the 2017 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:

The following nominee for a Class I director was elected to serve until the 2016 Annual Meeting of Shareholders and until his successor is duly elected and qualified based upon the following votes:

Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm

The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014 was approved based upon the following votes:

Proposal 3 – Advisory Vote on Executive Compensation

The resolution to approve, on an advisory basis, the compensation of the Company’s Named Officers as disclosed in the Proxy Statement was approved based upon the following votes:

Proposal 4 – Approval of 2014 Long-Term Incentive Plan

The proposal to approve the Plan was approved based upon the following votes:

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 18, 2014

EXHIBIT INDEX